Vaxart, a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, completed the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine.
The dataset will be highlighted in an oral presentation at the World Vaccine Congress (WVC), taking place from April 2-5, 2018 in Washington, USA.
The Phase 2 study was completed with support from the Biomedical Advanced Research and Development Authority (BARDA). Vaxart received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness
Vaxart, headquartered in San Francisco, USA, is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaccines developed by Vaxart are administered using a convenient room temperature-stable tablet, rather than by injection.
From company’s point of view the tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV).